Lipocine appoints Michael Grissinger to board of directors
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
Lipocine Inc. announced on August 3, 2026 that Michael J. Grissinger has joined its Board of Directors, effective immediately. The Board of Directors expanded to five members and appointed Grissinger as a director, effective August 3, 2026.1 The Board determined that Grissinger qualifies as an independent director under Nasdaq listing standards.1
Grissinger's career includes over 20 years at Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A.1 He also led the Immunology Therapeutic Area Business Development and Licensing Group and sat on the Immunology R&D/Commercial leadership team for J&J's Worldwide Immunology Franchise.1 Before Johnson & Johnson, he spent 12 years at Ciba-Geigy in finance, marketing, and business development.1 He currently serves on the boards of Aprea Therapeutics (Nasdaq: APRE) and Adicet Bio (Nasdaq: ACET),1 and advises several privately-held biotech companies.1 He holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University's Fox School of Business.1
As compensation, Grissinger will receive an initial stock option grant to purchase 2,000 shares of common stock, plus an annual retainer of $55,000 as a non-employee director.1 The filing states there are no family ties between Grissinger and other Lipocine directors or officers, and no related-party transactions requiring disclosure under SEC rules. His board term runs until Lipocine's next annual stockholders meeting, subject to earlier resignation, removal, or other departure as outlined in the filing.
Lipocine's pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 2401 for body composition in obesity management, LPCN 1148 for liver cirrhosis symptoms, and LPCN 1107 for prevention of preterm birth.1 The company also markets TLANDO, an FDA-approved oral testosterone prodrug for hypogonadism in adult males.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.